While pharmacologic therapies remain central to managing PsO and PsA, non-pharmacologic interventions also play a crucial ...

Psoriatic arthritis represents a complex intersection of immune dysfunction where inflammation targets both skin and joints, ...

Psoriatic arthritis is a combination of psoriasis and arthritis symptoms. You may have skin and nail changes, joint pain and ...

Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage ...

US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its ...

Delays in diagnosing and treating psoriatic arthritis—a common inflammatory disorder affecting around 200,000 people in the U ...

Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and ...

Johnson & Johnson (JNJ) reports a Phase 3 success for its anti-inflammatory drug Tremfya in treating psoriatic arthritis.

Johnson & Johnson announces positive results from phase 3b APEX study of Tremfya to treat adults living with active psoriatic arthritis: Spring House, Pennsylvania Monday, April 7 ...

Secukinumab treatment reduces bone erosion volume and enhances partial healing of erosions in patients with psoriatic ...

Degenerative disc disease is common among young adults with PsA, with key risk factors including older age, male sex, diabetes, and inflammatory back pain.